Pharmaceutical - Forxiga, Pricing


Current filters:


Popular Filters

UK's NICE backs NHS use of Bristol-Myers/AstraZeneca's Forxiga


UK drugs watchdog the National Institute for Health and Care Excellence (NICE) today (May 30) issued…

AstraZenecaBristol-Myers SquibbDiabetesEuropeForxigaPharmaceuticalPricingRegulation

Germany's IQWiG finds no added benefit for AstraZeneca and Bristol-Myers' Forxiga


In an early benefit assessment under the German Act on the Reform of the Market for Medicinal Products…

Bristol-Myers SquibbDiabetesEuropeForxigaPharmaceuticalPricingRegulation

Negative NICE guidance for Roche's Avastin and B-MS/AstraZeneca's Forxiga


UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) has published draft…

AstraZenecaAvastinBristol-Myers SquibbDiabetesEuropeForxigaOncologyPharmaceuticalPricingRegulationRoche

Scottish Medicines Consortium backs AstraZeneca/B-MS' Forxiga for type 2 diabetes


Anglo-Swedish drug major AstraZeneca (LSE: AZN) and partner Bristol-Myers Squibb (NYSE: BMY) of the USA…

AstraZenecaBristol-Myers SquibbDiabetesEuropeForxigaPharmaceuticalPricingRegulation

Back to top